Will Medicare cover Zepbound and other weight loss drugs in 2026?
Answered by 10 licensed agents
Starting July 1, 2026, Medicare is expected to provide access to certain GLP-1 weight loss drugs through what is called the Medicare GLP-1 Bridge program. This would apply to eligible people who have Medicare Part D coverage.
The drugs currently listed under this program include Foundayo, Wegovy, and Zepbound. For Zepbound, Medicare specifically lists the Zepbound KwikPen, not the single-dose vials or pens.
This is also a temporary program. It is scheduled to run from July 1, 2026 through December 31, 2027. One important detail is that this program operates outside the normal Part D payment system, which means Part D plans do not have to opt in for eligible beneficiaries to access the program.
The expected cost is a $50 copay for a one-month supply. However, that $50 does not count toward the Part D deductible or the annual out-of-pocket limit, and it cannot be reduced by Extra Help or LIS.
The biggest thing to understand is that eligibility is not simply based on wanting to lose weight. A provider would need to submit a prior authorization, and the patient would need to meet certain clinical requirements.
Those requirements may include BMI levels along with specific health conditions. For example, someone may qualify based on a BMI of 35 or higher, a BMI of 30 or higher with certain conditions such as heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of 27 or higher with conditions such as prediabetes, a prior heart attack, prior stroke, or peripheral artery disease.
It is also important to separate weight loss coverage from coverage for another medical diagnosis. If a GLP-1 medication is prescribed for a Medicare-coverable diagnosis, such as Type 2 diabetes, obstructive sleep apnea, or MASH, that would generally be reviewed through the person’s regular Part D plan, not the GLP-1 Bridge program.
So the short answer is yes, but not for everyone.
Answered by Matt Maresch on June 24, 2026
Agent Licensed in TX
Eligible Medicare beneficiaries can receive these medications for **$50 per month**, but there are specific requirements.
To qualify, you must have Medicare Part D prescription drug coverage and meet certain medical criteria, such as:
- A BMI of 35 or higher.
- A BMI of 30 or higher with certain medical conditions, such as uncontrolled high blood pressure, heart failure, or chronic kidney disease.
- A BMI of 27 or higher with certain conditions, including prediabetes or a history of heart attack or stroke.
Your doctor must prescribe the medication and obtain prior authorization.
It's important to understand that not everyone will qualify, and only certain versions of these medications are covered. The program is currently scheduled to continue through December 31, 2027.
If you're interested, I recommend speaking with your doctor to determine whether you meet the requirements.
Answered by Dustin Haffner on November 16, 2026
Agent Licensed in OK, AR, KS & MO
To qualify, you generally need to:
• Be enrolled in a Medicare Part D or Medicare Advantage plan with drug coverage
• Need the medication for weight loss (not for diabetes or another condition)
• Meet clinical criteria set by your doctor
• Have your doctor submit a prior authorization through the Bridge Program
This program runs through December 31, 2027 and operates separately from your regular Part D plan.
If you think you might qualify or just want to talk through whether this applies to your situation, please don’t hesitate to reach out. I’m happy to help!
Answered by Ali Hall on June 29, 2026
Broker Licensed in FL, AZ, CA & 10 other states
Starting July 1, 2026, Medicare covers certain GLP-1 drugs under the Medicare GLP-1 Bridge program. The covered drugs are Foundayo tablets, Wegovy as an injection or tablet, and Zepbound in the KwikPen only. The single-dose Zepbound pen and the vials are not covered.
Your cost is $50 per month, no matter your income level. You need to be in a Part D plan, and your prescriber has to get prior authorization and you must meet the eligibility criteria set by CMS.
Answered by Jose Ossorio on November 9, 2026
Agent Licensed in FL, AR, NC, OH, SC & TX
Answered by Rich Baker on June 24, 2026
Broker Licensed in CO, AR, AZ & 9 other states
Answered by Mary Brown on June 29, 2026
Broker Licensed in NJ, DE, FL & 5 other states
Answered by Vernon Jones on June 27, 2026
Broker Licensed in NC & SC
Medicare may cover Zepbound or similar medications if your doctor prescribes them for an FDA-approved medical condition, such as:
>Type 2 diabetes
>Obstructive sleep apnea (in some cases)
>Reducing cardiovascular risk
NOTE: In these situations, coverage depends on your specific Part D plan and whether the drug is on the formulary.
Bottom Line:
Pure weight loss = Not covered
Weight loss + another qualifying condition = Possibly covered
Answered by James Hale on June 26, 2026
Broker Licensed in GA, AL, FL & 5 other states
For the treatment of obesity and weight loss, you may be eligible to have Foundayo (tablet), Wegovy (injection or tablet) and Zepbound Kwikpen (injection) with a $50 copay.
If the pharmacy bills your drug plan, it will be rejected.
Answered by Kristina Guerry on June 25, 2026
Broker Licensed in SC, AL, AR & 45 other states
Beginning July 1, 2026, Medicare will make certain GLP-1 medications available to eligible Medicare Part D policyholders for the treatment of obesity and weight loss under the Bridge Program. This is a temporary in that will run through December 31, 2027.
Medicare will manage this program. This is separate from the Medicare Beneficiary’s Medicare Part D coverage.
Source: Anthem BC/BS Medicare.
Answered by Andrew Zurbuch, MBA on June 24, 2026
Broker Licensed in IN, FL, KY, MO, OH & TN
Tags: Coverage Medicare Part D Prescription Drug
Agents: Share Your Expertise
Have insights or experiences related to this topic? Help others by sharing your knowledge and answering this question.
Seniors: Ask a Question of Your Own
Questions are generally answered within 1 to 3 business days. Receive valuable perspectives from multiple licensed agents and brokers.
Ask a Question








